Compare NBIX & TKO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBIX | TKO |
|---|---|---|
| Founded | 1992 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 15.1B |
| IPO Year | 1996 | 2023 |
| Metric | NBIX | TKO |
|---|---|---|
| Price | $131.88 | $183.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 22 | 17 |
| Target Price | $180.82 | ★ $225.20 |
| AVG Volume (30 Days) | 1.0M | ★ 1.5M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.68% |
| EPS Growth | 41.95 | ★ 11200.00 |
| EPS | ★ 4.67 | 2.26 |
| Revenue | $161,626,000.00 | ★ $4,735,151,000.00 |
| Revenue This Year | $24.73 | $23.38 |
| Revenue Next Year | $13.14 | $0.89 |
| P/E Ratio | ★ $28.58 | $82.31 |
| Revenue Growth | ★ 977.51 | 68.85 |
| 52 Week Low | $100.83 | $144.00 |
| 52 Week High | $160.18 | $226.94 |
| Indicator | NBIX | TKO |
|---|---|---|
| Relative Strength Index (RSI) | 51.80 | 35.83 |
| Support Level | $124.29 | $181.26 |
| Resistance Level | $136.23 | $192.80 |
| Average True Range (ATR) | 4.36 | 6.47 |
| MACD | 0.20 | -0.99 |
| Stochastic Oscillator | 72.29 | 11.90 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
TKO Group Holdings Inc is a sports and sports entertainment company that operates combat sports and sports entertainment companies. It owns and manages valuable sports and entertainment intellectual property. The company distributes content and monetizes its intellectual property through four activities: Media rights, production, and content, Live events and hospitality, Partnerships and marketing and Consumer products licensing, The company has two reportable segments, UFC and WWE. The company generates majority of revenue from the UFC segment. The UFC segment revenue consists of media rights fees associated with the distribution of its programming content, ticket sales, and site fees associated with the business's international live events.